Scientific deep-dive

Does Anthem Cover Zepbound for Weight Loss? Honest Evidence Review

Yes on Anthem commercial plans that include weight-loss drugs, with PA (BMI ≥30, or ≥27 + a weight-related condition, plus a six-month supervised program unless an exception applies). Self-funded plans may exclude weight-loss drugs. Medicare covers Zepbound only for sleep apnea.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10 min read·15 citations

Short version: Anthem's commercial drug lists carry Zepbound with prior authorization, but only plans that include weight-loss drugs pay for it. On those plans, Anthem's Zepbound criteria (revised September 16, 2026) ask for a BMI of 30 or higher, or 27 or higher with a weight-related condition, plus six months in a provider-supervised diet and exercise program. That six-month requirement is waived for a BMI of 40 or higher, advanced heart failure, or moderate-to-severe sleep apnea, and the criteria do not make you try Wegovy first. Anthem Medicare Advantage cannot cover Zepbound for weight loss alone because of the federal Part D exclusion, but Part D can cover it for the FDA-approved sleep apnea indication. Self-funded employer plans can leave weight-loss drugs out entirely, which is the employer's call, not Anthem's. Below we cite Anthem's criteria and drug list, the federal exclusion statute, and the FDA label behind the sleep-apnea pathway.

The honest answer

Yes, with conditions, if your Anthem commercial plan includes weight-loss drugs: prior authorization, BMI ≥30 (or ≥27 with a weight-related condition), and six months in a supervised diet and exercise program unless an exception applies. First approvals last 36 weeks, and renewals need 5% weight loss. Anthem Medicare Advantage can cover Zepbound for sleep apnea through Part D, not for weight loss. Self-funded employer plans may exclude weight-loss drugs entirely. Always verify with your specific plan and group number. An earlier version of this page cited Anthem document CC-0188, which is Anthem's criteria for a different drug (Imcivree); we now cite Anthem's Zepbound criteria.

At a glance

  • Anthem commercial: YES with prior authorization if your plan includes weight-loss drugs. Zepbound is Tier 2 with prior authorization, a one-pen-a-week limit and a benefit-exclusion flag on the Virginia National Drug List, and it moved to Tier 3 on Anthem's California lists on January 1, 2026.[12][13]
  • Anthem self-funded employer (ASO): depends entirely on the employer. Many employers exclude weight-loss drug coverage even when the Anthem commercial formulary includes Zepbound. Ask HR or Benefits.
  • Anthem Medicare Advantage: NO for weight-loss-only Zepbound — federal Part D excludes agents “when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain.” [5] Part D can cover the separate FDA-approved moderate-to-severe obstructive sleep apnea indication (approved December 20, 2024), depending on your plan's formulary.[4][6]
  • Anthem Medicaid: varies by state. Virginia (Anthem HealthKeepers Plus) requires BMI >40, or >37 with dyslipidemia, hypertension or type 2 diabetes.[3] California Medi-Cal removed weight-loss GLP-1 coverage effective January 1, 2026.[2]
  • PA criteria: age 18+; BMI ≥30, or ≥27 with high blood pressure, type 2 diabetes, dyslipidemia, sleep apnea or cardiovascular disease, documented within 90 days; and six months in a supervised diet and exercise program with under 5% loss, which is waived at BMI ≥40, class III or IV heart failure, or AHI ≥15. [1]
  • Step therapy: none. Anthem's Zepbound criteria do not require trying Wegovy first, and Zepbound and Wegovy share Tier 2 on the Virginia National Drug List.[1][12]
  • Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027): eligible Part D enrollees can get Zepbound for weight management with a $50 copay, but only the Zepbound KwikPen formulation, not vials or single-dose pens. CMS decides eligibility from BMI and conditions such as prediabetes or a prior heart attack or stroke; people with type 2 diabetes, sleep apnea or MASH use regular Part D instead.[7][14][15]

Anthem commercial plans: covered with PA when weight-loss drugs are included

Anthem's Zepbound clinical criteria (revised September 16, 2026 and approved by the CarelonRx Pharmacy and Therapeutics Committee) are linked from each Zepbound entry in Anthem's commercial drug-list search.[1] The adult criteria:

  • Age 18 or older.
  • BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with at least one of these: high blood pressure (treated, or 130/80 or above), type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. The BMI must be documented within 90 days.
  • Six months in a provider-supervised program before the request: a calorie target about 500 kcal a day below your needs, 150 minutes of exercise a week unless you are clinically limited, and less than 5% weight loss. This is waived for BMI ≥ 40, NYHA class III or IV heart failure, or moderate-to-severe sleep apnea (AHI ≥ 15). You also have to stay in a supervised program during treatment.
  • First approval lasts 36 weeks. Renewals last one year and need documented 5% weight loss, achieved or maintained, recorded within 90 days of each renewal.
  • Not approved with a BMI under 18.5, a history of medullary thyroid carcinoma or MEN 2, or alongside another GLP-1 or tirzepatide product.

Out-of-pocket once PA is approved: your cost depends on your plan's tier and benefit design. Zepbound is Tier 2 on the Virginia National Drug List and Tier 3 on Anthem's California lists. The Lilly Zepbound Savings Card can lower the cost for eligible patients with commercial coverage, so check Lilly's current terms.

Anthem self-funded employer (ASO) plans — employer decides

This is the single biggest source of confusion. A large fraction of Anthem-branded plans are self-funded (also called “ASO” — Administrative Services Only). The employer pays claims directly from a corporate health trust; Anthem just rents out its provider network, claims-processing infrastructure, and pharmacy benefit manager (CarelonRx). On these plans the employer chooses whether to cover weight-loss drugs at all.

Even if Anthem's commercial formulary lists Zepbound as covered with PA, your specific self-funded employer can carve out anti-obesity medications as a non-covered benefit class — and many do, citing the cost. KFF and Mercer employer-survey data through 2025 showed roughly half of large self-funded employers excluded GLP-1 weight-loss agents from their benefits design.

How to tell if your Anthem plan is self-funded: ask HR or look at your Summary Plan Description (SPD) — it will say “self-insured” or “fully insured” somewhere in the plan-administration section. The SPD for a self-funded plan also typically lists the employer (not Anthem) as the “Plan Sponsor.” If self-funded, your appeals path goes through ERISA (federal law) and your employer's plan administrator — not through Anthem's state-insurance external review.

Anthem Medicare Advantage — NO for weight loss, YES for sleep apnea

Anthem Medicare Advantage plans operate under federal Medicare Part D rules. Social Security Act §1860D-2(e)(2)(A) explicitly excludes “agents when used for anorexia, weight loss, or weight gain” from Part D coverage.[5] This statutory exclusion is why no Medicare plan — Anthem MA-PD or otherwise — covers Zepbound for weight-loss-only indications today.

The sleep-apnea exception: on December 20, 2024, the FDA approved Zepbound as the first medication ever approved for moderate-to-severe obstructive sleep apnea in adults with obesity.[6] The Zepbound DailyMed label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b, label updated 04/22/2026) lists the second indication verbatim as: “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.” [4] Because OSA is a distinct FDA-approved indication — not weight loss — the §1860D-2(e)(2)(A) Part D exclusion does NOT apply, and Anthem MA-PD plans can cover Zepbound for OSA subject to PA. The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024, PMID 38912654) is the underlying evidence base.[10] For the full clinical picture, see our SURMOUNT-OSA tirzepatide / sleep apnea evidence article.

The Medicare GLP-1 Bridge (July 1, 2026 onward): a separate, time-limited federal program covers Wegovy (injection or tablet), Zepbound KwikPen only and Foundayo for weight management with a $50 copay through December 31, 2027. Anthem's provider notice says the patient must be 18 or older and must not have type 2 diabetes, moderate-to-severe sleep apnea or MASH, and that CMS decides final eligibility. The CMS request form asks for BMI at the start of therapy plus conditions such as prediabetes, a prior heart attack or stroke, peripheral artery disease, heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease. Because the Bridge runs outside the Part D benefit, CMS says the Part D deductible does not apply, none of the $50 copay counts toward your Part D out-of-pocket total, and Extra Help does not reduce it. [7][14][15]

Anthem Medicaid: state by state

Anthem runs Medicaid managed-care plans under state-specific names, such as Anthem HealthKeepers Plus in Virginia. Each state's Medicaid rules and Preferred Drug List apply, not Anthem's commercial criteria. Two examples:

  • Virginia (Anthem HealthKeepers Plus): the September 2026 Weight Loss Management PA Form requires BMI > 40 kg/m², or > 37 kg/m² with dyslipidemia, hypertension or type 2 diabetes, plus a failed non-GLP-1 weight-loss drug. Approvals last six months, and renewals need at least 5% weight loss since the last approval.[3]
  • California (Anthem Blue Cross Medi-Cal): under the November 14, 2025 notice, Wegovy, Zepbound and Saxenda left the Medi-Cal Rx drug list on January 1, 2026. Requests are still considered for Zepbound for obstructive sleep apnea and for Wegovy for MASH or cardiovascular disease, but weight-loss-only Zepbound is no longer covered.[2]

For an exhaustive state breakdown and the Medicare/commercial/ FEHB/Tricare/VA landscape, see our GLP-1 insurance coverage landscape article.

Step therapy: no Wegovy-first rule in Anthem's criteria

None of Anthem's published criteria requires you to try Wegovy before Zepbound. On the Virginia National Drug List (current as of October 1, 2026), Wegovy and Zepbound sit on the same tier with prior authorization, quantity limits and a benefit-exclusion flag, and neither has a step-therapy flag. California goes the other way: since January 1, 2026, Wegovy has been non-formulary on Anthem's California commercial lists while Zepbound is Tier 3.[1][12][13] If your own plan's drug list does show a step-therapy flag for Zepbound, Anthem has a step-therapy exception request, and the records below can support it.

If your plan does apply a step, these records tend to support an exception:

  • Less than 5% weight loss after a documented Wegovy trial at the maintenance dose.
  • Persistent intolerable adverse effects on Wegovy that did not resolve with dose adjustment (severe nausea, vomiting, injection-site reactions).
  • A contraindication to semaglutide that does not apply to tirzepatide (rare — both share the personal/family history of medullary thyroid carcinoma and MEN-2 boxed warnings).

For the operational detail, including Anthem's full Wegovy, Zepbound, Saxenda and Foundayo criteria, how CarelonRx and the drug lists fit together, and the appeal pathway, see our Anthem GLP-1 prior-authorization guide (the operational companion to this coverage answer). If your card says Blue Cross Blue Shield but you live outside Anthem's 14 states, a different Blue company sets the rules, and weight-loss coverage across those other Blues varies plan by plan.

Magnitude comparison

Typical monthly out-of-pocket cost for Zepbound by Anthem pathway. Commercial PA-approved with savings card is the cheapest brand option; cash-pay retail (no PA, no card) is the most expensive. Compounded tirzepatide via verified 503A telehealth is the cheapest path overall but is not brand Zepbound.[1][7][11]

  • Anthem commercial — PA approved + savings card25 $/mo
    lowest brand path
  • Anthem commercial — PA approved, no card75 $/mo
  • Anthem MA-PD — sleep apnea indication100 $/mo
    OSA only; not weight loss
  • Medicare GLP-1 Bridge (July 1, 2026)50 $/mo
    KwikPen only; bridge eligible
  • LillyDirect Self Pay vial — 2.5 mg starting dose299 $/mo
  • LillyDirect Self Pay vial — 7.5 mg therapeutic499 $/mo
  • LillyDirect Self Pay vial — 10/12.5/15 mg699 $/mo
  • Anthem denied — retail brand cash-pay (autoinjector)1,300 $/mo
    worst case
  • Compounded tirzepatide — 503A telehealth250 $/mo
    not brand Zepbound
Typical monthly out-of-pocket cost for Zepbound by Anthem pathway. Commercial PA-approved with savings card is the cheapest brand option; cash-pay retail (no PA, no card) is the most expensive. Compounded tirzepatide via verified 503A telehealth is the cheapest path overall but is not brand Zepbound.

What to do if Anthem denies your Zepbound PA

The Anthem appeals process gives commercial members 180 days from the denial notice to file a written internal appeal. The sequence:

  1. Get the written denial letter. It will name the specific clause your submission failed (BMI threshold, missing lifestyle-program documentation, step therapy not satisfied, formulary tier exception not requested, etc.).
  2. Identify the actual problem. Common causes are a plan that excludes weight-loss drugs, missing documentation of the six-month lifestyle program, or BMI and weight records older than 90 days.
  3. File an internal appeal with a Letter of Medical Necessity. Include baseline BMI, comorbidity documentation (HTN, T2D, dyslipidemia, or OSA diagnosis), the dated lifestyle-program records, and, if you qualify for an exception to the six-month program, documentation of BMI ≥40, class III or IV heart failure, or moderate-to-severe sleep apnea.
  4. If the internal appeal is denied, request an external review through Anthem's independent review organization (commercial fully-insured plans) OR through your state insurance department (some states require routing through them). External-review decisions are binding on commercial plans. For ERISA self-funded plans, the appeal goes through your employer's plan administrator and the U.S. Department of Labor — not Anthem.

Switching from Wegovy to Zepbound on Anthem

If you started on Wegovy under Anthem coverage and want to switch, Anthem's criteria do not require Wegovy to have failed. Your prescriber submits a Zepbound request under the Zepbound criteria:

  • If you are already on a GLP-1, the request is reviewed against the same criteria, so your starting BMI and the weight loss documented so far both matter.
  • Stop Wegovy when Zepbound starts, because Anthem will not approve two GLP-1 drugs at the same time.
  • For the dose-equivalence picture (Wegovy 2.4 mg ≈ Zepbound 5-10 mg starting territory), see our Wegovy → Zepbound switch dose-equivalence guide.

If Anthem denies — alternatives that actually work

While the appeal is in flight, the practical alternatives ranked by cost:

  • Compounded tirzepatide via verified 503A telehealth — typical $149-$349/month. Not brand Zepbound (the active pharmaceutical ingredient is the same, but quality and supply-chain rigor vary widely across compounding pharmacies). See our where-to-buy tirzepatide guide for the verified-provider directory.
  • LillyDirect Self Pay Pharmacy single-dose vials — $299/month (2.5 mg) → $399 (5 mg) → $499 (7.5 mg) → $699 (10/12.5/15 mg) as of the December 1, 2025 price reduction. The Zepbound self-pay program at $449/month is available to eligible patients on the 7.5 mg dose and above.[11]
  • Retail-pharmacy brand Zepbound autoinjector — list price typically $1,000-$1,300/month depending on dose. Avoid this path unless absolutely necessary; LillyDirect vials at the same effective dose are roughly half the cost.
  • Wait for Medicare GLP-1 Bridge (July 1, 2026) — for eligible Part D enrollees without type 2 diabetes, sleep apnea or MASH, with CMS deciding eligibility. $50 copay through December 31, 2027. Zepbound KwikPen only; vials and single-dose pens are NOT in the bridge.[7]

For mechanism-of-action context (SURMOUNT-1 demonstrated ~20.9% body-weight reduction at 72 weeks on tirzepatide 15 mg[8]; SURMOUNT-2 confirmed efficacy in T2D +obesity[9]), see our tirzepatide vs semaglutide head-to-head article.

Verdict — what most Anthem members should expect

For most Anthem-insured patients asking does Anthem cover Zepbound for weight loss: yes, if your commercial plan includes weight-loss drugs, with prior authorization, a BMI ≥30 (or ≥27 with a weight-related condition), and six months in a supervised program unless an exception applies. What you pay depends on your plan's tier.

The exceptions are the load-bearing details — verify all three before committing to a treatment plan:

  1. Is your plan self-funded? If yes, ask HR whether weight-loss medications are a covered benefit class. Anthem's commercial formulary tells you nothing if your employer carved them out.
  2. Are you on Anthem Medicare Advantage? If yes, weight-loss-only Zepbound is NOT covered today. Since December 20, 2024, Part D can cover sleep-apnea Zepbound if you have moderate-to-severe OSA, depending on your plan. The Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) opens a third path.
  3. Are you on Anthem Medicaid? Your state's Medicaid rules apply, not Anthem's commercial criteria. California Medi-Cal removed weight-loss GLP-1 coverage effective January 1, 2026; Virginia HealthKeepers Plus requires BMI > 40, or > 37 with a listed risk factor. Check your state.

For the side-effect picture once coverage is sorted, see our GLP-1 side-effect questions hub — the most-asked questions from active GLP-1 users with primary-source answers. For drug-specific reference data, see the Zepbound drug page and the tirzepatide active-ingredient page.

Disclaimer

This article is informational and does not constitute medical, financial, or legal advice. Insurance coverage decisions are made by your specific plan and employer, not by the criteria document Anthem publishes. Always verify coverage with the member-services number on the back of your insurance card and the group number on your benefits documents before committing to a treatment plan or paying out-of-pocket for a denial that may be appealable. Quoted PA criteria, BMI thresholds, and copays are sourced to the primary-source documents cited below and were current as of July 2026; payer policies change frequently.

Further reading

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Yes, if your Anthem commercial plan includes weight-loss drugs; Anthem's drug lists flag Zepbound as a possible benefit exclusion. Anthem's Zepbound criteria (revised September 16, 2026) require age 18 or older, a BMI of 30 or higher (or 27 or higher with high blood pressure, type 2 diabetes, dyslipidemia, sleep apnea or cardiovascular disease), and six months in a supervised diet and exercise program, unless your BMI is 40 or higher or you have class III or IV heart failure or moderate-to-severe sleep apnea. Self-funded employer (ASO) plans may exclude weight-loss drugs, which is the employer's decision, not Anthem's. Anthem Medicare Advantage cannot cover Zepbound for weight loss alone (federal Part D exclusion), but Part D can cover it for moderate-to-severe obstructive sleep apnea.
Yes. Anthem requires prior authorization for Zepbound. Its criteria: age 18 or older; a BMI of 30 or higher, or 27 or higher with a weight-related condition, documented within 90 days; six months in a supervised program with less than 5% weight loss, waived at a BMI of 40 or higher, class III or IV heart failure, or an AHI of 15 or higher; and continued participation in a program during treatment. The first approval lasts 36 weeks, and renewals last a year and require documented 5% weight loss.
Not for weight-loss-only indications. Social Security Act §1860D-2(e)(2)(A) excludes agents 'when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain' from Medicare Part D — and Anthem MA-PD plans operate under that federal exclusion. However, the FDA approved Zepbound on December 20, 2024, as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity, which is a separate FDA-approved indication. Anthem Medicare Advantage plans can cover Zepbound for OSA with prior authorization, depending on the plan's formulary. Separately, the CMS Medicare GLP-1 Bridge (July 1, 2026 through December 31, 2027) covers Zepbound KwikPen only (not vials or single-dose pens) for weight management with a $50 copay, for eligible Part D enrollees who do not have type 2 diabetes, sleep apnea or MASH. CMS decides eligibility.
With prior authorization approved, what you pay depends on your plan's tier and benefit design: Zepbound is Tier 2 on Anthem's Virginia National Drug List and Tier 3 on its California lists. The Lilly Zepbound Savings Card can lower the cost for eligible patients with commercial coverage; check Lilly's current terms. If Anthem denies the PA and you pay cash, LillyDirect Self Pay Pharmacy single-dose vials are $299/month (2.5 mg starting dose) through $699/month (10 mg, 12.5 mg, 15 mg) as of the December 1, 2025 price reduction. Retail-pharmacy brand Zepbound autoinjector cash-pay is typically $1,000-$1,300/month. Compounded tirzepatide via verified 503A telehealth is generally $149-$349/month but is not brand Zepbound.
A significant fraction of Anthem-branded plans are self-funded ASO plans where the employer (not Anthem) decides which drug classes are covered. Even if the Anthem commercial formulary lists Zepbound as covered with PA, your employer can exclude anti-obesity medications as a non-covered benefit class — and many do. To check: ask HR or look at your Summary Plan Description, which will say 'self-insured' or 'fully insured' in the plan-administration section. If self-funded, your appeal goes through ERISA and your employer's plan administrator (and ultimately the U.S. Department of Labor) — not through Anthem's state-insurance external review. Alternatives if your self-funded plan excludes Zepbound: LillyDirect Self Pay Pharmacy vials ($299-$699/month) or compounded tirzepatide via verified 503A telehealth ($149-$349/month).
Yes, after the FDA's December 20, 2024 approval of Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity. The Zepbound DailyMed label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b) lists the second indication verbatim as 'to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.' Because OSA is a distinct FDA-approved indication, the federal Part D weight-loss exclusion does NOT apply, and Anthem Medicare Advantage plans CAN cover Zepbound for OSA subject to prior authorization. Anthem commercial plans similarly cover Zepbound for OSA. PA documentation typically requires an apnea-hypopnea index (AHI) of at least 15 events per hour — the SURMOUNT-OSA trial entry criterion that anchored the FDA approval.
It varies by state. Anthem runs Medicaid managed-care plans under state-specific names, and each state's Medicaid rules apply instead of Anthem's commercial criteria. Two examples: Virginia (Anthem HealthKeepers Plus) requires a BMI greater than 40, or greater than 37 with dyslipidemia, hypertension or type 2 diabetes, plus a failed non-GLP-1 weight-loss drug. California's Medi-Cal program removed Wegovy, Zepbound and Saxenda for weight loss on January 1, 2026, per Anthem's November 14, 2025 notice; requests are still considered for Wegovy for MASH or cardiovascular disease and for Zepbound for sleep apnea. Check your state's Medicaid rules directly.
Anthem's published Zepbound criteria have no step-therapy requirement and do not require trying Wegovy first. On the Virginia National Drug List, Zepbound and Wegovy are both Tier 2 with prior authorization and no step-therapy flag. The real prerequisite is six months in a supervised diet and exercise program, unless your BMI is 40 or higher or you have class III or IV heart failure or moderate-to-severe sleep apnea. If your own plan's drug list shows a step-therapy flag, ask about Anthem's step-therapy exception form.
Commercial Anthem members have 180 days from the denial notice to file a written internal appeal. Steps: (1) get the written denial letter naming the specific clause your submission failed; (2) identify the actual problem — common reasons are a plan that excludes weight-loss drugs and missing documentation of the six-month lifestyle program; (3) file the internal appeal with a Letter of Medical Necessity that includes baseline BMI, comorbidity documentation, dated lifestyle-program records, and records supporting any exception to the six-month program; (4) if the internal appeal is denied, request an external review through Anthem's independent review organization (commercial fully-insured plans) or through your state insurance department, where binding decisions can be made. For ERISA self-funded plans, the appeal goes through your employer's plan administrator and the U.S. Department of Labor — not Anthem.
Yes. Anthem's criteria do not require Wegovy to fail before Zepbound. Your prescriber submits a request under Anthem's Zepbound criteria, and Wegovy has to stop when Zepbound starts, because Anthem will not approve two GLP-1s at once. On dosing, Wegovy 2.4 mg sits roughly in the Zepbound 5-10 mg starting range in head-to-head exposure data, so a 5 mg or 7.5 mg Zepbound start is typical after a Wegovy 2.4 mg run.
Yes, on Anthem commercial plans that include weight-loss drugs, with prior authorization under Anthem's Zepbound criteria: a BMI of 30 or higher, or 27 or higher with a weight-related condition, plus six months in a supervised program unless an exception applies. Two 2026 changes matter. On January 1, 2026, Anthem moved Zepbound to Tier 3 on its California commercial lists, and California's Medi-Cal program dropped weight-loss GLP-1s the same day. From July 1, 2026 through December 31, 2027, the CMS Medicare GLP-1 Bridge offers Zepbound KwikPen with a $50 copay to eligible Part D enrollees without type 2 diabetes, sleep apnea or MASH. Anthem Medicare Advantage still cannot cover weight-loss-only Zepbound under the federal Part D exclusion, though Part D can cover the separate sleep apnea indication. Because self-funded employer plans and state Medicaid programs set their own rules, verify your specific plan and group number for the current year before assuming coverage.

References

  1. 1.Anthem Blue Cross and Blue Shield; CarelonRx Pharmacy and Therapeutics Committee. Zepbound (tirzepatide) clinical criteria: chronic weight management. Revised September 16, 2026. Linked as Clinical Criteria from Anthem's commercial drug-list search (anthem.com/pharmacy-information). 2026. https://fm.formularynavigator.com/FormularyNavigator/DocumentManager/Download?clientDocumentId=uQnefMVvOkyWWxbLFQEp8w
  2. 2.Anthem Blue Cross (California). GLP-1 Coverage Considerations (Medi-Cal), November 14, 2025. Wegovy, Zepbound and Saxenda removed from the Medi-Cal Rx Contract Drugs List effective January 1, 2026; PA still considered for Wegovy (MASH or cardiovascular disease) and Zepbound (OSA). providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf. 2025. https://providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf
  3. 3.Anthem HealthKeepers Plus (Virginia Medicaid). Weight Loss Management Prior Authorization Form (September 2026, VA-BCBS-CD-019947-26). GLP-1 criteria: BMI >40, or >37 with dyslipidemia, hypertension or type 2 diabetes; failed non-GLP-1 weight-loss drug; 6-month approvals. providers.anthem.com/docs/gpp/VA_CAID_WeightLossMgmtPAForm.pdf. 2026. https://providers.anthem.com/docs/gpp/VA_CAID_WeightLossMgmtPAForm.pdf
  4. 4.Eli Lilly. Zepbound (tirzepatide) injection — Highlights of Prescribing Information. Indications: chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity. dailymed.nlm.nih.gov SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b (label updated 04/22/2026). 2026.
  5. 5.Centers for Medicare & Medicaid Services (CMS). Social Security Act §1860D-2(e)(2)(A) — Part D excluded drugs (agents when used for weight loss). ssa.gov/OP_Home/ssact/title18/1860D-2.htm. 2024.
  6. 6.U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea (Zepbound expanded indication, 12/20/2024). fda.gov news release 12/20/2024. 2024.
  7. 7.Centers for Medicare & Medicaid Services (CMS). Medicare GLP-1 Bridge: time-limited coverage of Wegovy, Zepbound KwikPen and Foundayo, July 1, 2026 through December 31, 2027. FAQ: $50 copay; Part D deductible does not apply; copay does not count toward TrOOP. cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
  8. 8.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PMID: 35658024.
  9. 9.Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, et al.; SURMOUNT-2 Investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. PMID: 37385275.
  10. 10.Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024. PMID: 38912654.
  11. 11.Eli Lilly. LillyDirect Self Pay Pharmacy — Zepbound single-dose vial cash-pay tiers (effective 12/01/2025): 2.5 mg $299, 5 mg $399, 7.5 mg $499, 10/12.5/15 mg $699. Zepbound self-pay program: $449 (7.5 mg and above) for eligible patients. lillydirect.lilly.com pricing snapshot. 2026.
  12. 12.Anthem Blue Cross and Blue Shield. Virginia National Drug List, 3 Tier (current as of October 1, 2026). Zepbound Tier 2 with PA, BE and QL (1 pen per week). fm.formularynavigator.com (linked from anthem.com/pharmacy-information). 2026. https://fm.formularynavigator.com/FBO/143/National_3_Tier_ABCBSVa.pdf
  13. 13.Anthem Blue Cross and Blue Shield. January formulary deletions (Commercial). Published March 1, 2026, effective January 1, 2026. Anthem Provider News. 2026. https://providernews.anthem.com/virginia/articles/january-formulary-deletions-28766
  14. 14.Anthem Blue Cross and Blue Shield. Prepare prescriptions for the Medicare Bridge program (Medicare Advantage). September 24, 2026. Anthem Provider News. 2026. https://providernews.anthem.com/virginia/articles/prepare-prescriptions-for-the-medicare-bridge-program-32351
  15. 15.Centers for Medicare & Medicaid Services (CMS). Medicare GLP-1 Bridge Prior Authorization Request Form. cms.gov. 2026. https://www.cms.gov/files/document/glp-1-bridge.pdf

Anthem GLP-1 Prior Authorization Guide: Wegovy, Zepbound, Saxenda and Foundayo Criteria

Anthem's current commercial PA criteria for Wegovy, Zepbound, Saxenda and Foundayo, from the CarelonRx-approved documents on Anthem's drug lists, plus Virginia Medicaid, California Medi-Cal and Medicare Bridge rules and how Anthem compares with Aetna and Cigna.

14 min read

Does Blue Cross Blue Shield Cover Weight Loss Drugs? Honest Coverage Review

Blue Cross Blue Shield is ~33 independent companies plus the FEP, with no single formulary. T2D GLP-1s are widely covered with PA; weight-loss GLP-1s vary by plan, and some Blues dropped them in 2025–2026. Medicare members may use the $50 GLP-1 Bridge.

12 min read

Does Aetna Cover GLP-1 Weight Loss Drugs? Honest Coverage Review

Aetna's pharmacy benefit is run by CVS Caremark. T2D GLP-1s are covered with PA; Wegovy, Zepbound and Foundayo for weight loss only if your employer added the AOM benefit. Zepbound returned to Caremark formularies 10/1/2026; Medicare members may qualify for the $50 GLP-1 Bridge.

11 min read

Does Humana Cover Weight Loss Drugs? Honest Coverage Review

Humana is mainly a Medicare insurer, so federal Part D law excludes weight-loss-only Wegovy, Zepbound, and Saxenda. T2D GLP-1s, Zepbound for sleep apnea, and Wegovy for heart risk or MASH are coverable with PA. The CMS GLP-1 Bridge offers $50/month since July 2026.

11 min read

Does Kaiser Permanente Cover Weight Loss Drugs? Honest Coverage Review

It depends on your region and plan tier. Kaiser covers type 2 diabetes GLP-1s with internal prior authorization, but weight-management coverage of Wegovy, Zepbound and Saxenda varies, and large employers often exclude it. KP Medi-Cal in California dropped them Jan 1, 2026.

11 min read

Does UnitedHealthcare Cover Weight Loss Drugs? OptumRx Coverage Review

UnitedHealthcare covers type 2 diabetes GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus) with prior authorization, but excludes weight-loss drugs under most plans unless the employer opts in. Medicare members may qualify for the $50 Medicare GLP-1 Bridge.

12 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $129/mo (sale price)

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $179/mo (prepaid plan rate)

Get started →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

From $239/mo (12-month plan rate)

Get started →